90 related articles for article (PubMed ID: 1426095)
1. Negative regulators of hematopoietic stem cells and progenitors.
Dainiak N
Exp Hematol; 1992 Nov; 20(10):1154-5. PubMed ID: 1426095
[No Abstract] [Full Text] [Related]
2. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
Wierenga PK; Konings AW
Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
[TBL] [Abstract][Full Text] [Related]
3. The stem cell compartment: assays and negative regulators.
Wright EG; Pragnell IB
Curr Top Microbiol Immunol; 1992; 177():137-49. PubMed ID: 1638868
[No Abstract] [Full Text] [Related]
4. Seraspenide (AcSDKP) mediated protection of hematopoietic stem cells in a hyperthermic purging protocol.
Wierenga PK; Konings AW
Prog Clin Biol Res; 1994; 389():189-95. PubMed ID: 7700902
[No Abstract] [Full Text] [Related]
5. Stem cell proliferation inhibitors.
Wright EG; Pragnell IB
Baillieres Clin Haematol; 1992 Jul; 5(3):723-39. PubMed ID: 1457966
[No Abstract] [Full Text] [Related]
6. Suppressive biological activity of a synthetic pentapeptide on highly enriched human and murine marrow hematopoietic progenitors: synergism with recombinant human tumor necrosis factor-alpha and interferon-gamma.
Lu L; Foa P; Chillemi F; Shen RN; Lin ZH; Carow C; Broxmeyer HE
Exp Hematol; 1989 Oct; 17(9):935-41. PubMed ID: 2506072
[TBL] [Abstract][Full Text] [Related]
7. The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors.
Paukovits JB; Rutter R; Ganglberger E; Karlic HI; Marian B; Paukovits WR
Mol Pharmacol; 1999 Oct; 56(4):665-74. PubMed ID: 10496948
[TBL] [Abstract][Full Text] [Related]
8. Effects of small peptidic inhibitors of murine stem cells on human normal and malignant cells.
Guigon M; Bonnet D; Césaire R; Lemoine F; Najman A
Ann N Y Acad Sci; 1991; 628():105-14. PubMed ID: 2069291
[No Abstract] [Full Text] [Related]
9. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP.
Guigon M; Bonnet D; Lemoine F; Kobari L; Parmentier C; Mary JY; Najman A
Exp Hematol; 1990 Nov; 18(10):1112-5. PubMed ID: 2209766
[TBL] [Abstract][Full Text] [Related]
10. Photoprotection of normal human hematopoietic progenitors by the tetrapeptide N-AcSDKP.
Coutton C; Guigon M; Bohbot A; Ferrani K; Oberling F
Exp Hematol; 1994 Oct; 22(11):1076-80. PubMed ID: 7925774
[TBL] [Abstract][Full Text] [Related]
11. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
Jackson JD; Yan Y; Ewel C; Talmadge JE
Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
[TBL] [Abstract][Full Text] [Related]
12. The tetrapeptide AcSerAspLysPro (Seraspenide), a hematopoietic inhibitor, may reduce the in vitro toxicity of 3'-azido-3'-deoxythymidine to human hematopoietic progenitors.
Grillon C; Bonnet D; Mary JY; Lenfant M; Najman A; Guigon M
Stem Cells; 1993 Sep; 11(5):455-64. PubMed ID: 8241956
[TBL] [Abstract][Full Text] [Related]
13. Hemoregulatory peptide (HP5b) dimer effects on normal and malignant cells in culture.
Frostad S; Kalland T; Aakvaag A; Laerum OD
Stem Cells; 1993 Jul; 11(4):303-11. PubMed ID: 8401253
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hematopoietic stem cell proliferation by hemoregulatory peptide pyroGlu-Glu-Asp-Cys-Lys (pEEDCK) provides protection against short-term neutropenia and long-term damage.
Paukovits WR; Moser MH; Rutter R; Paukovits JB
Ann N Y Acad Sci; 1991; 628():92-104. PubMed ID: 2069326
[No Abstract] [Full Text] [Related]
15. Can human hematopoietic stem cells be cultured ex vivo?
Verfaillie CM
Stem Cells; 1994 Sep; 12(5):466-76. PubMed ID: 7528589
[TBL] [Abstract][Full Text] [Related]
16. [The hematopoietic stem cell: biology and clinical applications].
Consolini R; Legitimo A; Calleri A
Pathologica; 2001 Feb; 93(1):2-14. PubMed ID: 11294014
[TBL] [Abstract][Full Text] [Related]
17. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells.
Bonnet D; Césaire R; Lemoine F; Aoudjhane M; Najman A; Guigon M
Exp Hematol; 1992 Feb; 20(2):251-5. PubMed ID: 1544396
[TBL] [Abstract][Full Text] [Related]
18. Special susceptibility to apoptosis of CD1a+ dendritic cell precursors differentiating from cord blood CD34+ progenitors.
Canque B; Camus S; Yagello M; Gluckman JC
Stem Cells; 1998; 16(3):218-28. PubMed ID: 9617897
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of hemoregulatory peptide (HP5b) action in culture.
Laerum OD; Aakvaag A; Frostad S; Kalland T; Langen P; Maurer HR
Int J Cell Cloning; 1990 Nov; 8(6):431-44. PubMed ID: 2273297
[TBL] [Abstract][Full Text] [Related]
20. Effect of the hemoregulatory peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1alpha is reduced in bone marrow cultures from patients with chronic myeloid leukemia (CML).
Karlic H; Louda N; Pfeilstöcker M; Keil F; Lohninger A; Pittermann E; Paukovits J
Stem Cells; 2001; 19(4):321-8. PubMed ID: 11463952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
